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Abstract Background Hyperhomocysteinaemia may constitute an independent risk factor for car-
diovascular disease, but it is still unclear by which pathophysiological mechanisms homo-
cysteine (tHcy) may promote atherothrombosis. The aim of this study was ®rstly to examine
whether tHcy is associated with endothelial dysfunction, increased adherence of leukocytes,
and/or chronic low-grade in¯ammation, as estimated from plasma levels of von Willebrand
factor (vWf), soluble vascular cell adhesion molecule 1 (sVCAM-1) and C-reactive protein
(CRP), respectively. Secondly we investigated whether the presence of type 2 diabetes
modi®es these associations.
Materials and Methods Six hundred and ten subjects of a general population of middle-
aged and elderly subjects, 170 of whom had type 2 diabetes, participated in this cross-
sectional study. Linear regression analyses were used to study whether tHcy was associated
with vWf, sVCAM-1 and CRP, and whether the presence of diabetes modi®ed these
associations.
Results After adjustment for confounders, tHcy was signi®cantly but weakly associated
with vWf (b 0´15, P 0´05) and sVCAM-1 (b 0´082, P 0´04). tHcy was not signi®-
cantly associated with CRP (b 0´02, P 0´91). The presence of diabetes did not sig-
ni®cantly modify these associations.
Conclusions This study provides evidence that tHcy is, at most, weakly associated with
endothelial dysfunction as estimated from plasma vWf, and with leukocyte adhesion as
estimated from plasma sVCAM-1. tHcy was not signi®cantly associated with chronic low-
grade in¯ammation as estimated from plasma CRP. Our data thus suggest that the link
between tHcy and atherothrombosis cannot be explained by associations of tHcy with vWf,
sVCAM-1 or CRP.
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type 2 diabetes.
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Introduction
Many studies provide evidence for an independent associa-
tion between hyperhomocysteinaemia and atherothrombo-
tic disease, as recently reviewed [1]. However, the strength
of the association between an elevated total homocysteine
(tHcy) concentration and cardiovascular disease seems to
vary among populations [2]. Four recent studies in popula-
tions with diabetic subjects demonstrated that hyperhomo-
cysteinaemia is a strong risk factor for cardiovascular
disease in subjects with type 2 diabetes [3±6]. For diabetic
subjects, tHcy appeared to be a 1´6-fold stronger risk factor
for cardiovascular disease than for non-diabetics [3].
tHcy is derived metabolically from the essential amino
acid methionine. Homeostasis of methionine-homocys-
teine metabolism is complex and is in¯uenced by demo-
graphic, genetic, and acquired factors. It is not fully
understood by which pathophysiological mechanisms
tHcy promotes atherothrombosis in humans. Recent stu-
dies suggest that tHcy is a vasculotoxic molecule that
mediates its adverse vascular effects by causing endothelial
damage [7±13]. Impairment of regulatory functions of the
endothelium is a key event in current models of athero-
thrombosis [13]. In addition, tHcy may cause an increased
adherence of leukocytes to the endothelium, mediated by
an increased expression of adhesion molecules, as observed
in early atherosclerosis [13±15]. An alternative hypothesis
is that tHcy induces a chronic low-grade in¯ammation,
thus promoting the atherogenetic process [13].
Previous studies concerning the pathophysiological
mechanisms by which tHcy may promote atherothrombo-
sis have either examined a study group that was not
population-based or did not assess the strength of the
association separately for type 2 diabetes and non-diabetics
[7±12]. The latter is important because diabetes and tHcy
seem to interact [3]. Therefore, we assessed, in a popula-
tion-based study that was strati®ed for glucose tolerance
[16], the association between tHcy level and endothelial
dysfunction by measuring plasma levels of the endothe-
lium-derived regulatory protein, von Willebrand factor
(vWf). We also assessed the association between tHcy
and the soluble form of vascular cell adhesion molecule 1
(sVCAM-1) as an estimate of the adherence and transen-
dothelial migration of leukocytes; and ®nally, between tHcy
and C-reactive protein, a marker of chronic low-grade
in¯ammation. The use of these protein markers is sup-
ported by studies showing an association between high
plasma or serum levels of these proteins and an increased
risk of cardiovascular disease [17±26].
Methods
Subjects
The study population consisted of an age-, sex-, and
glucose-tolerance-strati®ed sample of the Hoorn Study, a
population-based study of glucose tolerance and other
cardiovascular risk factors in a 50- to 75-year-old general
Caucasian population conducted from 1989±1992, as
described previously [16].
Brie¯y, 2484 subjects (71% of those invited) partici-
pated. All subjects, except previously diagnosed diabetic
subjects treated with oral glucose-lowering agents or insu-
lin, underwent an oral glucose tolerance test (OGTT)
according to the WHO guidelines [27]. For reasons of
ef®ciency, subjects with a 2-h postload glucose
$ 7´5 mmol Lÿ1, all subjects with type 2 diabetes and a
random sample of subjects with a 2-h postload glucose
< 7´5 mmol Lÿ1 strati®ed by age and sex were invited within
4 weeks for a second visit to investigate glucose-intoler-
ance-related complications (709 invited, of whom 631 ÿ
89% ÿ participated). These subjects underwent a second
OGTT (except those who already used blood glucose
lowering agents; n67). On the basis of the mean of the
two OGTTs, glucose tolerance was divided into three
categories [16]: normal glucose tolerance (n 288),
impaired glucose tolerance (n 170) and type 2 diabetes
(n 173). Subjects with normal or impaired glucose toler-
ance or type 2 diabetes in the present study population thus
represented a strati®ed random sample of all subjects with
normal or impaired glucose tolerance or type 2 diabetes in
the initial cohort.
The Hoorn Study was approved by the Ethical Review
Committee of the University Hospital Vrije Universiteit.
Informed consent was obtained from all participants.
Laboratory and clinical assessments
After an overnight fast, blood was drawn from an ante-
cubital vein. We measured tHcy, vWf, VCAM-1, CRP,
glucose, creatinine, albumin, urea nitrogen and lipids. No
plasma was available for 21 subjects for the measurement of
vWf, sVCAM-1 and CRP. Concentrations of serum total
(free plus protein bound) tHcy were assessed in frozen
(ÿ 20 8C) EDTA serum by using high-performance liquid
chromatography with ¯uorescence detection [28]. The
intra-and interassay coef®cients were 2´1% and 5´1%,
respectively. Plasma concentrations of von Willebrand
factor (vWf) and C-reactive protein (CRP) were assessed
as previously described [26]. VWf is expressed in IU mLÿ1
of vWf antigen by comparison to the 4th International
Standard for vWf in plasma [26]. The intra-and interassay
coef®cients of variation of CRP were 3´8% and 4´7%,
respectively. Concentrations of sVCAM-1 were assessed
in deep frozen (ÿ 70 8C) heparin plasma samples. Concen-
trations of sVCAM-1 were measured, in duplicate, by
ELISA kits (Bender MedSystems, Wenen, Austria; refer-
ence plasma values in 111 healthy subjects, as provided by
the manufacturer, 1090 6 237 ng mLÿ1; range 675±1693).
We measured sVCAM-1 levels in 27 healthy volunteers and
found a mean level of 966 ng mLÿ1 with an intra-and
interassay coef®cient of variation of 3´4% and 14%, respec-
tively [23]. Serum total cholesterol, HDL cholesterol, and
triglycerides levels were all measured as described else-
where [3]. We estimated the glomerular ®ltration rate by
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the method of Levey et al. which is thought to be more
accurate than the Cockcroft±Gault formula [29]. Blood
pressure was measured as the mean of four measurements
performed on two different occasions, using a random-zero
sphygmomanometer under standardized conditions.
Hypertension was de®ned as a blood pressure
$ 160 mmHg systolic and/or $ 95 mmHg diastolic and/or
the current use of antihypertensive medication. Subjects
were classi®ed as current cigarette smokers or nonsmokers.
Body mass index (BMI) and waist-to-hip ratio (WHR)
were calculated as described elsewhere [16]. ABO blood
groups were determined by standard agglutination techni-
ques using commercial test erythrocytes.
Statistical analysis
Variables are presented as mean 6 standard deviation
(SD), number (percentage of the total), or, in case of a
skewed distribution, the median and the interquartile range
(IQR). To study whether tHcy is independently related to
vWf, VCAM-1 and CRP, and whether this differs between
subjects with type 2 diabetes and those with impaired or
normal glucose tolerance, we constructed crude and
adjusted regression models. Analyses adjusted only for
the strati®cation variables age, sex and glucose tolerance
(i.e. normal glucose tolerance, impaired glucose tolerance,
and type 2 diabetes) were used to study the relation
between the outcome variables (vWf, VCAM-1, CRP)
and possible determinants thereof: tHcy, glomerular ®ltra-
tion rate (GFR), smoking, total cholesterol, HDL choles-
terol, LDL cholesterol, triglycerides, systolic and diastolic
blood pressure, hypertension, BMI and the WHR. For
variables that did not have a normal distribution of the
residuals, the logarithmically transformed data were used
for a better ®t of the data. Possible determinants measured
on a continuous scale were used as such in the regression
models. For each dependent variable three regression
models were made. The regression analyses were primarily
adjusted for the strati®cation variables, secondarily for all
determinants with a P-value <0´15 in the crude analysis
and current smoking, and thirdly for other variables of
pathophysiological interest [30]. The residuals were
checked for a normal distribution and a constant variance.
In addition, to check whether there was a threshold in the
relation between tHcy and the dependent variables, we
performed analyses in which we divided tHcy into four
categories (# 10 mmol Lÿ1, 10´1±15´0 mmol Lÿ1, 15´1±
20´0 mmol Lÿ1 and $ 20´1 mmol Lÿ1, respectively). To
ascertain whether the presence of cardiovascular disease
at enrolment disturbed the results, we performed the same
analysis as described above for the subjects with and with-
out a history of cardiovascular disease. Cardiovascular
disease was de®ned as coronary artery disease, cerebrovas-
cular disease and or peripheral arterial disease as described
before [3]. vWf depends on blood group, and therefore we
Table 1 General characteristics of the subjects
All Subjects Non-diabetic subjects Diabetic subjects
Number 610 440 170
Men (%) 48´7 50´2 44´7
Age (yr) 64´3(7´2) 63´7(7´3) 65´9(6´7)
BMI (kg m2±1) 27´3(4´0) 26´7(3´5) 28´9(4´6)
WHR (men) 0´97(0´07) 0´96(0´07) 1´0(0´07)
WHR (women) 0´87(0´07) 0´86(0´07) 0´92(0´06)
Current smoker (%) 26´3 28´2 21´4
Systolic blood pressure (mmHg) 139´4(19´5) 137´6(19´5) 144´2(18´7)
Diastolic blood pressure (mmHg) 82´5(10´0) 82´3(9´9) 83´1(10´3)
Hypertension (%) 39´5 33´2 55´9
Total cholesterol (mmol Lÿ1) 6´6(1´2) 6´7(1´2) 6´5(1´3)
HDL cholesterol (mmol Lÿ1) 1´3(0´4) 1´3(0´4) 1´2(0´3)
LDL cholesterol (mmol Lÿ1) 4´5(1´1) 4´6(1´0) 4´3(1´1)
Triglycerides (mmol Lÿ1) 1´9(1´3) 1´7(0´9) 2´4(1´8)
Glomerular ®ltration rate (mL minÿ1)* 69´8(20´0) 69´3(18´8) 70´9(22´8)
Total homocysteine (mmol L²) 11´4 1´6 11´3
(9´3±14´1) (9´4±14´4) (9´3±13´6)
Von Willebrand factor (IU mL²) 1´22 1´12 1´56
(0´86±1´73) (0´82±1´62) (0´99±2´10)
Soluble vascular cell 1304´8 1273´3 1402´3
adhesion molecule (mglL²) (1090´8±1594´6) (1051´0±1563´7) (1184´3±1753´7)
C-reactive protein (mg Lÿ1) 1´8 1´5 2´5
(0´83±3´8) (0´7±3´2) (1´3±4´7)
Data are presented as mean (SD), percentage of the total or median (interquartile range).
*Estimated by the method of Levey et al. [29], ²median (interquartile range).
BMI, body mass index; WHR, waist-to-hip ratio; HDL cholesterol, high density lipoprotein cholesterol; LDL
cholesterol, low density lipoprotein cholesterol.
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performed strati®ed analyses for the different blood groups
to investigate if blood group modi®ed the association
between tHcy and vWf. Finally we investigated whether
glucose tolerance was an effect modi®er of the tHcy-out-
come relationships by adding product terms to the analysis
(i.e. product terms of tHcy with impaired glucose tolerance
and tHcy with type 2 diabetes). With an F-test we checked
whether these product terms signi®cantly improved the
model. All analyses were performed with the SPSS. Two-
sided P-values less than 0´05 were considered to be statis-
tically signi®cant.
Results
Table 1 shows the characteristics of the participants.
Twenty-one subjects had missing blood samples, so we
obtained complete data in 610 participants, 170 (28%) of
whom had type 2 diabetes. The median tHcy serum level
was 11´4 (IQR: 9´3±14´1) mmol Lÿ1. One hundred 25
(21%) subjects had a tHcy level $ 15 mmol Lÿ1, the cut-
off value frequently used to de®ne a high tHcy level [1±31].
tHcy was signi®cantly but weakly associated with vWf
(b 0´198; P 0´004; Fig. 1a; Table 2a) after adjustment for
the strati®cation variables. Adjustment for other possible
confounders, especially GFR, weakened this association
(b 0´150; P 0´046), but it remained signi®cant. A 50%
increase in the concentration of tHcy was associated with an
increase in the concentration of vWf with 0´08 IU mLÿ1.
Thus, for example, when the concentration of tHcy increased
from 10 to 15 mmol Lÿ1, the level of vWf increased with 0´08
IU mLÿ1 (95% con®dence interval (C.I.), 0´01±0´22
IU mLÿ1). In comparison, type 2 diabetes, as compared to
normal glucose tolerance, was associated with a 0´39
IU mLÿ1 (95% C.I., 0´23±0´56 IU mLÿ1) higher vWf
level, after adjustment for age, sex, current smoking, LDL
cholesterol and GFR, but the presence of diabetes did not
modify the association between tHcy and vWf (P-interaction
 0´34 after exclusion of one diabetic subject with an
extremely high tHcy level).
After adjustment for the strati®cation variables there was
a signi®cant but weak association between tHcy and
sVCAM-1 (b 0´130; P 0´001). Adjustment for other
possible confounders, especially GFR, weakened this asso-
ciation (b 0´082; P 0´041; Fig. 1b; Table 2b), but it
remained signi®cant. For example, when the concentration
of tHcy increased from 10 to 15 mmol Lÿ1, the concentra-
tion of sVCAM-1 increased with 60´9 mg Lÿ1 (95% C.I.,
19´6±144´6 mg Lÿ1). In comparison, type 2 diabetes, as
compared to normal glucose tolerance, was associated
with a 146´2-mg Lÿ1 (95% C.I. 30´9±270´8 mg Lÿ2) higher
sVCAM-1 level, after adjustment for age, sex, current
smoking, LDL cholesterol, HDL cholesterol, GFR, BMI
and hypertension, but the presence of diabetes did not
modify the association between tHcy and sVCAM-1 (P-
interaction  0´79).
There was no signi®cant association of tHcy with CRP in
any model (Fig. 1c; Table 2c). When the concentration of
tHcy increased from 10 to 15 mmol Lÿ1, the concentration
of CRP increased with 0´01 mg Lÿ1 (95% C.I., ÿ 0´01±
0´01 mg Lÿ1). In addition, the presence of diabetes did not
modify the association between tHcy and CRP (P-interac-
tion  0´17).
The results did not differ signi®cantly between the
subjects with and without cardiovascular disease at enrol-
ment (data not shown). In addition, the relation between
vWf and tHcy was not modi®ed by blood group (data not
shown).
Our analysis did not suggest any threshold in the relation
between tHcy and the dependent variables (data not
shown).
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Figure 1 Plots with the 5th (dot), 10th, 25th, 50th, 75th, 90th
and 95th (dot) percentiles as vertical boxes of the univariate rela-
tion between fasting concentrations of serum total homocysteine
(in quintiles) and plasma von Willebrand factor, soluble vascular
cell adhesion molecule 1 and C-reactive protein.
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Discussion
This is the ®rst study that evaluates the association between
tHcy and markers of endothelial function, leukocyte adhe-
sion and low-grade in¯ammation in a population-based
study with a focus on diabetes.
Hyperhomocysteinaemia may predispose to athero-
thrombosis by injuring the vascular endothelium. We
assessed endothelial function by measuring vWf, an
endothelial protein, increased levels of which are associated
with an adverse cardiovascular outcome [17±19,26,32±
35]. We found that tHcy was associated with a signi®cant,
but small change in the vWf concentration. If we assume
that this association is causal, a relatively large increase in
tHcy (which is clearly associated with increased mortality
in this population [36]) induces a relatively minor increase
in vWf. Such minor increases in vWf were not strongly
associated with increased mortality in the present popula-
tion, because the association between vWf and mortality
was non-linear and restricted to subjects with vWf >1´56
IU/mL [26]. Accordingly, our results suggest that if tHcy
does in fact induce endothelial dysfunction, this is not
re¯ected by an increased level of vWf. Three previous
studies concerning vWf and tHcy showed a positive corre-
lation in subjects with peripheral arterial occlusive disease
[7±9]. In contrast, a study in hyperlipidaemic male smo-
kers showed a signi®cant negative correlation between tHcy
and vWf [37]. A recent study performed by de Roo et al.
demonstrated a weak positive relation between tHcy and
the endothelial proteins vWf and endothelin in healthy
Table 2a Multiple linear regression analysis with ln von Willebrand factor (vWf in IU mLÿ1) as the
outcome variable and homocysteine (tHcy) as the independent variable of interest
Percentage change (95% C.I.) in
vWf (IU mLÿ1) associated with a
Model b ln tHcy (95% C.I.) P-value 50% increase in tHcy
1 0´198 (0´062±0´334) 0´004 8´36 (1´73±14´5)
2 0´150 (0´002±0´297) 0´046 6´27 (0´08±12´8)
3 0´149 (0´001±0´296) 0´049 6´23 (0´04±12´75)
Model 1: the independent variables were ln tHcy and the strati®cation variables glucose tolerance,
age and sex. Model 2: as model 1 plus the variables with a P-value <0´15 in the crude analysis (LDL
cholesterol, glomerular ®ltration rate) and current smoking. Model 3: as model 2 plus other variables
of interest (body mass index, waist-to-hip ratio, hypertension, HDL cholesterol).
Table 2b Multiple linear regression analysis with ln soluble vascular cell adhesion molecule 1
(sVCAM-1 in mg/L) as the outcome variable and tHcy as the independent variable of interest
Percentage change (95% C.I.) in
sVCAM-1 (mg Lÿ1) associated with
Model b ln tHcy (95% C.I.) P-value a 50% increase in tHcy
1 0´130 (0´054±0´206) 0´001 5´41 (2´21±8´71)
2 0´082 (0´002±0´162) 0´041 3´38 (0´08±6´79)
3 0´080 (0´001±0´160) 0´045 3´3 (0´04±6´7)
Model 1: the independent variables were ln tHcy and the strati®cation variables glucose tolerance,
age and sex. Model 2: as model 1 plus the variables with a P-value <0´15 in the crude analysis (cur-
rent smoking, LDL cholesterol, HDL cholesterol, glomerular ®ltration rate, body mass index, hyper-
tension). Model 3: as model 2 plus other variables of interest (waist-to-hip ratio).
Table 2c Multiple linear regression analysis with ln C-reactive protein (CRP in mg Lÿ1) as the out-
come variable and tHcy as the independent variable of interest
Percentage change (95% C.I.) in
CRP (mg Lÿ1) associated with a
Model b ln tHcy (95% C.I.) P-value 50% increase in tHcy
1 0´082 (ÿ0´240±0´404) 0´611 3´39 (0±17´8)
2 0´017 (ÿ0´239±0´381) 0´912 0´69 (0±16´71)
3 0´017 (ÿ0´229±0´439) 0´530 0´69 (0±19´48)
Model 1: the independent variables were ln tHcy and the strati®cation variables glucose tolerance,
age and sex. Model 2: as model 1 plus the variables with a P-value <0´15 in the crude analysis (cur-
rent smoking, body mass index, waist-to-hip ratio, HDL cholesterol, hypertension). Model 3: as
model 2 plus other variables of interest (glomerular ®ltration rate, LDL cholesterol).
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postmenopausal women [38]. Taken together, these studies
and the current data suggest that there is a weak association
between tHcy and vWf in the general (mostly healthy)
population, and that this association may be magni®ed in
the presence of other factors, such as peripheral arterial
occlusive disease. This would be consistent with studies
suggesting that mild hyperhomocysteinaemia, at least in
some populations, appears more strongly associated with
the progression of atherothrombotic disease than with its
initiation [39±41]. As the prevalence of cardiovascular
disease was 10´6% [3], our study lacked power to investi-
gate this issue, but this hypothesis clearly requires further
study.
We examined whether hyperhomocysteinaemia was
associated with an increased recruitment of leukocytes as
re¯ected by plasma levels of sVCAM-1, a member of the
immunoglobin superfamily that plays an important role in
the recruitment of mononuclear leukocytes to the endothe-
lium [14,15]. A 50% increase in tHcy was associated with a
60´9 mg Lÿ1 increase in sVCAM-1 levels, which corre-
sponds with a 6% increase in 7-year mortality risk [23].
This weak association between tHcy and sVCAM-1 does
not provide strong evidence in favour of the hypothesis that
tHcy is associated with an increased adherence of leuko-
cytes to the endothelium, a hypothesis recently proposed by
Dudman [42]. Our ®nding is in line with a recent study that
demonstrated a signi®cant association between sVCAM-1
and carotid intimal medial thickness, a surrogate measure-
ment of early atherosclerosis, but not between sVCAM-1
and tHcy [21].
We further investigated whether tHcy was related to
CRP. CRP is an acute phase reactant and increased levels
may re¯ect a chronic low-grade in¯ammatory state.
Increased CRP levels have been shown to be an independent
predictor of atherothrombotic events [19,24±26,43±46].
In the population investigated, tHcy was not associated
with CRP. This may imply that hyperhomocysteinaemia
does not promote atherothrombosis by contributing to low-
grade in¯ammation.
Kuller et al. have argued that the relation between tHcy
and atherogenesis may not be causal, but, that conversely,
vascular disease may induce an increase in the concentra-
tion of tHcy [47]. They suggest that the in¯ammation in
atherosclerosis is associated with an increased mitotic
activity and results in a shortage of folic acid, which is
used in DNA synthesis. Folic acid is also essential in the
metabolism of tHcy and the increased demand on folic acid
would lead to a secondary elevation of tHcy levels. To test
this theory we performed a multiple regression analysis
with CRP as the independent and tHcy as the dependent
variable. However, this analysis also did not suggest a
relation between tHcy and CRP (data not shown).
A shortcoming of this study might be that folate, vitamin
B6 and B12 status were not measured. Although there is no
evidence that inadequate B-vitamin status can directly
cause a raise in plasma vWf, sVCAM-1 or CRP, we
cannot fully exclude this.
In conclusion, this study provides evidence that, in a
general population of middle-aged and elderly subjects
with and without type 2 diabetes, tHcy is, at most,
weakly associated with endothelial dysfunction as esti-
mated from plasma vWf, and with leukocyte adhesion as
estimated from plasma sVCAM-1. tHcy was not associated
with chronic low-grade in¯ammation as estimated from
plasma CRP. Our data thus suggest that the link between
tHcy and atherothrombosis cannot be explained by asso-
ciations of tHcy with vWf, sVCAM-1 or CRP. We cannot
exclude that these associations may be stronger in speci®c
patient groups. The present data do provide evidence
against the hypothesis that the chronic low-grade in¯am-
mation that is part of the atherosclerotic process is itself a
determinant of tHcy levels.
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